A. Andersson

发表

Premenopausal serum sex hormone levels in relation to breast cancer risk, overall and by hormone receptor status—Results from the EPIC cohort

F. Clavel-Chapelon, E. Riboli, A. Tjønneland, 2014, International journal of cancer.

Plasma 25‐hydroxyvitamin D and the risk of breast cancer in the European prospective investigation into cancer and nutrition: A nested case–control study

J. Chang-Claude, F. Clavel-Chapelon, E. Riboli, 2013, International journal of cancer.

Physical activity and risk of breast cancer overall and by hormone receptor status: The European prospective investigation into cancer and nutrition

F. Clavel-Chapelon, A. Fournier, F. Berrino, 2013, International journal of cancer.

Alcohol Consumption and Survival after a Breast Cancer Diagnosis: A Literature-Based Meta-analysis and Collaborative Analysis of Data for 29,239 Cases

J. Chang-Claude, F. Clavel-Chapelon, E. Riboli, 2014, Cancer Epidemiology, Biomarkers & Prevention.

High risk of cardiovascular side effects after treatment of Hodgkin’s lymphoma – is there a need for intervention in long-term survivors?

M. Erlanson, B. Melin, G. Enblad, 2021, Upsala journal of medical sciences.

Risk of second primary malignancies in women with breast cancer: Results from the European prospective investigation into cancer and nutrition (EPIC)

J. Chang-Claude, F. Clavel-Chapelon, E. Riboli, 2015, International journal of cancer.

Insulin‐like growth factor I and risk of breast cancer by age and hormone receptor status—A prospective study within the EPIC cohort

I. Gram, F. Clavel-Chapelon, E. Riboli, 2014, International journal of cancer.

Surgical treatment of breast cancer liver metastases - A nationwide registry-based case control study.

M. Sund, A. Andersson, H. Taflin, 2020, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Healthy lifestyle and risk of breast cancer among postmenopausal women in the European Prospective Investigation into Cancer and Nutrition cohort study

S. Rosso, E. Riboli, K. Overvad, 2015, International journal of cancer.

Reproductive factors and risk of hormone receptor positive and negative breast cancer: a cohort study

F. Clavel-Chapelon, A. Fournier, F. Berrino, 2013, BMC Cancer.

Long-term side effects after treatment of Hodgkin's lymphoma

A. Andersson, 2011 .

Family history of cancer as a risk factor for second malignancies after Hodgkin's lymphoma

M. Björkholm, B. Malmer, G. Enblad, 2008, British Journal of Cancer.

Dietary fat intake and development of specific breast cancer subtypes.

F. Clavel-Chapelon, F. Berrino, E. Riboli, 2014, Journal of the National Cancer Institute.

Height, age at menarche and risk of hormone receptor‐positive and ‐negative breast cancer: A cohort study

V. McCormack, I. Gram, E. Riboli, 2013, International journal of cancer.

Genetic Polymorphisms in Vitamin D Metabolism and Signaling Genes and Risk of Breast Cancer: A Nested Case-Control Study

Eva Lundin, Tomas Axelsson, Göran Hallmans, 2015, PloS one.

Circulating prolactin and breast cancer risk among pre- and postmenopausal women in the EPIC cohort.

S. Rosso, F. Clavel-Chapelon, E. Riboli, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Docetaxel, trastuzumab, pertuzumab versus trastuzumab emtansine as neoadjuvant treatment of HER2-positive breast cancer: Results from the Swedish PREDIX HER2 trial identifying a new potential de-escalation standard?

J. Bergh, J. Bjöhle, A. Bosch, 2019, Journal of Clinical Oncology.

Weight change in middle adulthood and breast cancer risk in the EPIC‐PANACEA study

J. Chang-Claude, F. Clavel-Chapelon, E. Riboli, 2014, International journal of cancer.

Long‐term risk of cardiovascular disease in Hodgkin lymphoma survivors—Retrospective cohort analyses and a concept for prospective intervention

B. Malmer, G. Enblad, U. Näslund, 2009, International journal of cancer.

Estrogen therapy after breast cancer diagnosis and breast cancer mortality risk

S. Margolin, A. Valachis, H. Garmo, 2023, Breast Cancer Research and Treatment.

Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer: A Phase 2 Randomized Clinical Trial.

J. Bergh, J. Hartman, J. Bjöhle, 2021, JAMA oncology.

Long term risk of infections in Hodgkin lymphoma long‐term survivors

M. Erlanson, B. Melin, G. Enblad, 2011, British journal of haematology.

Reproductive factors and risk of hormone receptor positive and negative breast cancer: a cohort study

F. Clavel-Chapelon, A. Fournier, F. Berrino, 2013, BMC Cancer.

Circulating prolactin and breast cancer risk among pre- and postmenopausal women in the EPIC cohort.

S. Rosso, F. Clavel-Chapelon, E. Riboli, 2014 .

Insulin‐like growth factor I and risk of breast cancer by age and hormone receptor status—A prospective study within the EPIC cohort

I. Gram, F. Clavel-Chapelon, A. Tjønneland, 2014, International journal of cancer.